Can group visits boost buprenorphine success for opioid users?

NCT ID NCT02526212

Completed Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving buprenorphine treatment in group medical visits (instead of one-on-one) helps people with opioid use disorder stay abstinent and remain in treatment. Eighteen adults already on buprenorphine but still using opioids took part in weekly 90-minute group sessions for 8 weeks. The goal was to see if peer support and shared medical care could improve outcomes and lower HIV risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine
What this could lead to: If it works, this could point toward a more effective way to deliver buprenorphine treatment for opioid use disorder, potentially reducing relapse and HIV risk.
What could go wrong: This was a very small pilot study (18 participants) with no control group for comparison. Results may not apply to larger or more diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-RELATED DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-RELATED DISORDERS

Contacts and locations

Locations

Comprehensive Health Care Center

The Bronx, New York, 10451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.